Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Redfield

Showing results (1031-1040 of 1,078) with videos related to

Pageof 108
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|August 25, 2018
Specific oxylipins enhance vertebrate hematopoiesis via the receptor GPR132Jamie L Lahvic, Michelle Ammerman, Pulin Li, et al.
Journal of the American Heart Association|November 19, 2021
Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HFLeanne Mooney, Nathaniel M Hawkins, Pardeep S Jhund, et al.
JACC. Heart Failure|July 10, 2020
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE TrialDouglas L Mann, Stephen J Greene, Michael M Givertz, et al.
JACC. Heart Failure|March 15, 2025
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HFToru Kondo, Pardeep S Jhund, Inder S Anand, et al.
Circulation. Heart Failure|June 23, 2023
Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial FibrillationToru Kondo, Karola S Jering, Pardeep S Jhund, et al.
JACC. Heart Failure|August 4, 2018
Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical TrialsKishan S Parikh, Kavita Sharma, Mona Fiuzat, et al.
JACC. Heart Failure|July 1, 2017
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF TrialScott D Solomon, Adel R Rizkala, Jianjian Gong, et al.
The New England Journal of Medicine|November 10, 2015
Isosorbide Mononitrate in Heart Failure with Preserved Ejection FractionMargaret M Redfield, Kevin J Anstrom, James A Levine, et al.
European Journal of Heart Failure|August 31, 2024
Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fractionShingo Matsumoto, Alasdair D Henderson, Li Shen, et al.
Circulation|June 6, 2024
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HFPooja Dewan, Li Shen, João Pedro Ferreira, et al.
Pageof 108

Showing results (1031-1040 of 1,078) with videos related to

Sort By:
Pageof 108
Proceedings of the National Academy of Sciences of the United States of America|August 25, 2018
Specific oxylipins enhance vertebrate hematopoiesis via the receptor GPR132Jamie L Lahvic, Michelle Ammerman, Pulin Li, et al.
Journal of the American Heart Association|November 19, 2021
Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HFLeanne Mooney, Nathaniel M Hawkins, Pardeep S Jhund, et al.
JACC. Heart Failure|July 10, 2020
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE TrialDouglas L Mann, Stephen J Greene, Michael M Givertz, et al.
JACC. Heart Failure|March 15, 2025
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HFToru Kondo, Pardeep S Jhund, Inder S Anand, et al.
Circulation. Heart Failure|June 23, 2023
Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial FibrillationToru Kondo, Karola S Jering, Pardeep S Jhund, et al.
JACC. Heart Failure|August 4, 2018
Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical TrialsKishan S Parikh, Kavita Sharma, Mona Fiuzat, et al.
JACC. Heart Failure|July 1, 2017
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF TrialScott D Solomon, Adel R Rizkala, Jianjian Gong, et al.
The New England Journal of Medicine|November 10, 2015
Isosorbide Mononitrate in Heart Failure with Preserved Ejection FractionMargaret M Redfield, Kevin J Anstrom, James A Levine, et al.
European Journal of Heart Failure|August 31, 2024
Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fractionShingo Matsumoto, Alasdair D Henderson, Li Shen, et al.
Circulation|June 6, 2024
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HFPooja Dewan, Li Shen, João Pedro Ferreira, et al.
Pageof 108